2025
IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerCarcinoma in situImpact of tumor stageBCG-unresponsiveRadical cystectomyUpfront RCCancer-specific mortalityOncological outcomesTumor stageT1 patientsAll-cause mortalityTA patientsPathological outcomesPapillary diseaseHigh risk of recurrenceBCG-unresponsive diseaseClinical stage tumorsUpfront radical cystectomyClinical tumor stageNode-positive diseaseCompare oncologic outcomesInvasive bladder cancerT1 stage tumorsKaplan-Meier methodUtility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer.
Linhares S, Srikumar T, Shin C, Mathur M, Mongiu A, Leeds I, Pantel H, Cecchini M. Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer. Journal Of Clinical Oncology 2025, 43: 45-45. DOI: 10.1200/jco.2025.43.4_suppl.45.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNeoadjuvant immune checkpoint inhibitorsPathological stageDMMR tumorsPMMR tumorsColon cancerSurgical resectionT stageRadiographic stagePathologic complete response rateUtilization of computed tomographyClinically staged patientsNode negative tumorsRate of understagingComplete response rateLocally advanced diseaseNode-positive diseaseClinical tumor stageNode-positive tumorsUpfront surgical resectionCorrelated to pathological stagingPrimary tumor growthLocalized colon cancerLow relapse rateEarly stage tumors
2024
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer
Pusztai L, Hoag J, Albain K, Barlow W, Stemmer S, Meisner A, Hortobagyi G, Shak S, Rae J, Baehner R, Sharma P, Kalinsky K. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer. Journal Of Clinical Oncology 2024, 43: 919-928. PMID: 39621968, PMCID: PMC11885031, DOI: 10.1200/jco-24-01507.Peer-Reviewed Original ResearchChemoendocrine therapyRecurrence scorePostmenopausal womenClinicopathological factorsClinicopathological modelOncotype DX Breast Recurrence ScoreLymph node-positive breast cancerInvasive disease-free survivalNode-positive breast cancerHormone receptor-positiveNode-positive diseaseDisease-free survivalCox proportional hazards regression modelsIndividual recurrence riskProportional hazards regression modelsRisk estimatesHealth Service RegistryEstimation of prognosisHazards regression modelsPremenopausal patientsEndocrine therapyReceptor-positiveChemotherapy benefitMenopausal statusPatient-level dataPre-Operative Boost Results in Low Rates of Re-Excision and Reduced Time from Initial Diagnosis to Completion of Local-Regional Treatment in Breast Cancer Patients
Chakraborty M, Sherwani Z, Yehia Z, Ohri N, Cui T, Eladoumikdachi F, Kowzun M, Kumar S, Potdevin L, Toppmeyer D, Haffty B. Pre-Operative Boost Results in Low Rates of Re-Excision and Reduced Time from Initial Diagnosis to Completion of Local-Regional Treatment in Breast Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s201-s202. DOI: 10.1016/j.ijrobp.2024.07.2265.Peer-Reviewed Original ResearchBreast-conserving surgeryWhole breast irradiationDuctal carcinoma in situRe-excision ratesProspective phase II clinical trialRate of re-excisionPhase II clinical trialRe-excisionII clinical trialsHypofractionated regimenWound complicationsPre-operativelyDiagnosis to completionTreated with breast-conserving surgeryClinical trialsInitiation of systemic therapyMedian clinical tumor sizeRisk of wound complicationsIncidence of wound complicationsEarly-stage breast cancerLocal-regional treatmentTumor bed boostClinical tumor sizeNode-positive diseaseCompletion of radiationOutcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers
Zakeri K, Shang T, Yu Y, Chen L, Shamseddine A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e807. DOI: 10.1016/j.ijrobp.2024.07.1772.Peer-Reviewed Original ResearchP16-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomasOropharyngeal squamous cell carcinomaDistant recurrenceSquamous cell carcinomaNodal recurrenceRadiotherapy doseLocoregional recurrenceP16 statusCell carcinomaHypopharynx cancerP16-negative oropharyngeal cancerHead and neck cancer patientsRadiation doseElective nodal volumesP16-negative diseaseNode-positive diseaseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent cetuximabConcurrent chemotherapyLocoregional controlMedian followNodal diseaseDevelopment and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
Pusztai L, Hoag J, Albain K, Barlow W, Stemmer S, Meisner A, Hortobagyi G, Shak S, Hayes D, Rae J, Baehner F, Sharma P, Kalinsky K. Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer. Journal Of Clinical Oncology 2024, 42: 508-508. DOI: 10.1200/jco.2024.42.16_suppl.508.Peer-Reviewed Original ResearchChemoendocrine therapyRecurrence scoreClinicopathological factorsBreast cancerPostmenopausal patientsNode-negative breast cancerNode-positive breast cancerHormone receptor-positiveNode-positive diseaseHR+/HER2- breast cancerRisk estimatesHigh-risk patientsEstimating 5-year riskEstimation of recurrence riskLikelihood ratioPremenopausal patientsHER2-negativeReceptor-positiveChemotherapy benefitEndocrine therapyMenopausal statusRisk patientsInvasive diseasePrognostic informationPostmenopausal modelFactors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes
Shulman R, Deng M, Handorf E, Meyer J, Lynch S, Arora S. Factors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes. JAMA Network Open 2024, 7: e240044. PMID: 38421650, PMCID: PMC10905315, DOI: 10.1001/jamanetworkopen.2024.0044.Peer-Reviewed Original ResearchConceptsPathological complete responseLocally advanced rectal cancerSocial determinants of healthRate of pathological complete responseNon-Hispanic Black patientsNon-Hispanic white patientsDeterminants of healthNational Cancer DatabaseNeoadjuvant therapyPN0 statusTumor downstagingSocial determinantsEthnic disparitiesRectal cancerCancer DatabaseRates of tumor downstagingWhite patientsLymph node-positive diseaseNon-Hispanic black raceTreatment outcomesBlack patientsAssociated with treatment responseNon-Hispanic blacksNon-Hispanic whitesNode-positive disease
2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian followNodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy
Mittendorf EA, Kantor O, Weiss A, Richardson E, Garrido-Castro A, Portnow LH, Krop IE, Lin NU, Winer EP, Tolaney SM, King TA. Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. Annals Of Surgical Oncology 2022, 30: 100-106. PMID: 35941343, DOI: 10.1245/s10434-022-12357-8.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNational Cancer DatabaseNormal clinical examinationAxillary ultrasoundNegative clinical examinationClinical examinationUpfront surgeryCT2 tumorsInstitutional databaseBreast cancerEarly-stage triple-negative breast cancerStage triple-negative breast cancerAddition of immunotherapyNodal positivity ratePathologic nodal statusNode-positive patientsEvent-free survivalNode-positive diseaseRisk-benefit ratioCT1-2N0NCDB cohortPreoperative immunotherapyResultsFor patientsPositive nodesPreoperative chemotherapyAssociation of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2021
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma
Gao Y, Wang M, Guo X, Hu J, Chen TM, Finn S, Lacy J, Kunstman JW, H. C, Bellin MD, Robert ME, Desir GV, Gorelick FS. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. PLOS ONE 2021, 16: e0250539. PMID: 34587190, PMCID: PMC8480607, DOI: 10.1371/journal.pone.0250539.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Pancreatic DuctalCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMonoamine OxidaseNeoplasm GradingPancreatic NeoplasmsPrognosisProspective StudiesRetrospective StudiesSurvival AnalysisUp-RegulationYoung AdultConceptsPlasma renalase levelsBorderline resectable PDACRenalase levelsPDAC precursor lesionsOverall survivalPDAC tissuesTumor characteristicsResectable PDACChronic pancreatitisPrecursor lesionsNormal pancreasPancreatic ductal adenocarcinoma growthAdvanced tumor characteristicsVaried clinical stagesWorse tumor characteristicsNode-positive diseasePancreatic ductal adenocarcinomaNormal pancreatic headSpindle-shaped cellsPlasma renalaseRenalase expressionUnderwent resectionAbdominal traumaPancreatic headPositive diseaseExamination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study
Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.Peer-Reviewed Original ResearchConceptsLung neuroendocrine tumorsLymph nodesNeuroendocrine tumorsLung carcinoidsSSTR imagingLN metastasisAtypical carcinoidExact testSingle-institution retrospective cohort studyLymph node-positive diseaseAssociation of lymphPositive lymph nodesRetrospective cohort studyLymph node diseaseLymph node involvementNode-positive diseaseLymph node metastasisMultivariable logistic regressionFisher's exact testPre-operative workupN2 diseaseAdjuvant therapyLN involvementN1 diseaseNode involvement
2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 26-32. PMID: 33145460, PMCID: PMC7598436, DOI: 10.1016/j.adro.2020.10.003.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultationsOncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research And Treatment 2020, 185: 215-227. PMID: 32939592, DOI: 10.1007/s10549-020-05931-9.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPN1 breast cancerRecurrence scoreChemotherapy useBreast cancerOverall survivalChemotherapy receiptPN1 patientsRS testingUse of RSNode-positive breast cancerOncotype DX recurrence scoreAdjuvant chemotherapy receiptLow genomic riskNode-positive diseaseAdjuvant treatment decisionsLow recurrence scoreShort-term outcomesMultivariate logistic regressionComprehensive cancer centerDX recurrence scoreOncotype DX testingChemotherapy omissionPT1-2N0Upfront surgeryExpanding criteria for prognostic stage IA disease in HR+ breast cancer.
Kantor O, King T, Shak S, Russell C, Giuliano A, Hortobagyi G, Burstein H, Winer E, Sparano J, Mittendorf E. Expanding criteria for prognostic stage IA disease in HR+ breast cancer. Journal Of Clinical Oncology 2020, 38: 550-550. DOI: 10.1200/jco.2020.38.15_suppl.550.Peer-Reviewed Original ResearchStage IA diseaseRecurrence scoreIA diseaseN categoryOncotype DX recurrence scoreNode-positive diseaseAJCC staging systemDX recurrence scoreRS resultsRS 11Median followDSS ratesPositive diseaseSEER databaseReceptor statusStaging systemEvidence of utilityScore 11Breast cancerTrial dataDiseaseAdditional studiesPatientsStagingDSSProstate Cancer Radiation Therapy Recommendations in Response to COVID-19
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances In Radiation Oncology 2020, 5: 659-665. PMID: 32292839, PMCID: PMC7118610, DOI: 10.1016/j.adro.2020.03.010.Peer-Reviewed Original ResearchProstate cancerM1 diseaseNational Comprehensive Cancer Network risk groupClinical node-positive diseaseFavorable intermediate-risk diseaseRadiation therapy recommendationsIntermediate-risk diseaseNeoadjuvant hormone therapyNode-positive diseaseStage of diseaseTreatment of patientsProstate cancer stageRadiation oncology departmentsGlobal pandemicAdjuvant radiationModerate hypofractionationHormone therapyPositive diseaseRoutine visitsCancer stageTherapy recommendationsOncology departmentRisk groupsRadiation therapyTelemedicine consultations
2019
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal Of Clinical Oncology 2019, 38: 725-733. PMID: 31809240, PMCID: PMC7048163, DOI: 10.1200/jco.19.01959.Peer-Reviewed Original ResearchConceptsNode-positive breast cancerDistant recurrence-free survivalRecurrence scoreBreast cancerBreast Cancer StudyN0 diseaseN1 diseaseYoung womenYoung Women's Breast Cancer StudyPositive/HER2-negative breast cancerHER2-negative breast cancerHuman epidermal growth factor receptorEarly distant recurrenceEarly-stage estrogenN0 breast cancerRS risk groupsNode-positive diseaseMinority of patientsRecurrence-free survivalYears of ageEpidermal growth factor receptorGrowth factor receptorDistant recurrenceAxillary nodesEligible women
2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Godellas C, Chen M, Kalinsky K, Hibshoosh H, Killelea B, Sanft T, Hirst G, Asare S, Matthews J, Perlmutter J, Esserman L, and I-SPY 2 Investigators. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer 2018, 4: 26. PMID: 30131975, PMCID: PMC6098077, DOI: 10.1038/s41523-018-0074-6.Peer-Reviewed Original ResearchAxillary lymph node dissectionLymph node dissectionClinical trialsNeoadjuvant chemotherapyNode dissectionPositive diseaseDrug therapy trialsI-SPY2 trialManagement of axillaBreast cancer clinical trialsNode-positive diseaseProspective clinical trialsMulticenter clinical trialAssessment of responseClinical trial dataCancer clinical trialsNeoadjuvant settingPrimary endpointNodal involvementSurgical resectionSurgical managementProper stagingResidual diseaseSurgical standardAxillaSurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed Complex General Surgical Oncology 2018 DOI: 10.2310/7800.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgerySurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed CGSO Case-Based Reviews 2018 DOI: 10.2310/cgso.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply